📊 RMTI Key Takeaways
Is Rockwell Medical, Inc.. (RMTI) a Good Investment?
Revenue collapse of 31.8% YoY combined with operating losses, negative operating cash flow, and free cash flow of -$592K indicate severe operational distress. Gross margin of 16.7% is critically low for the pharmaceutical sector (typically 70-80%), suggesting fundamental competitive or pricing challenges. Company is burning cash and lacks clear path to profitability without dramatic turnaround.
Rockwell Medical’s fundamentals are challenged by a 31.8% YoY revenue contraction, negative operating and net margins, and weak returns (ROE/ROA). While liquidity is strong and leverage is low, interest coverage is negative and EPS deterioration suggests dilution risk; without top-line stabilization and margin expansion, a path to durable profitability remains unclear.
Why Buy Rockwell Medical, Inc.. Stock? RMTI Key Strengths
- Strong liquidity position with current ratio of 3.74x and quick ratio of 3.43x
- Conservative leverage with debt-to-equity ratio of only 0.23x limits financial risk
- Cash balance of $9.6M provides near-term operational runway
- Strong liquidity with 3.98x current and 3.63x quick ratios
- Low leverage (0.24x debt/equity) providing flexibility
- Modest cash burn with near-breakeven operating cash flow and low capex
RMTI Stock Risks: Rockwell Medical, Inc.. Investment Risks
- Catastrophic 31.8% revenue decline YoY indicates loss of market share or product demand collapse
- Negative operating cash flow (-$167K) and free cash flow (-$592K) show company is not self-sustaining
- Gross margin of 16.7% is dangerously low for pharma; suggests structural cost/pricing dysfunction or product obsolescence
- Negative interest coverage ratio (-3.4x) means operations cannot support debt obligations
- Current cash burn rate will exhaust $9.6M reserve within 16+ months without operational improvement
- Continued double-digit revenue declines pressure scale and fixed-cost absorption
- Persistent negative margins and returns (operating, net, ROE/ROA)
- Negative interest coverage and potential future dilution to fund operations
Key Metrics to Watch
- Revenue stabilization and YoY growth recovery
- Gross margin improvement toward industry norms (70%+)
- Return to positive operating cash flow
- Cash runway and monthly burn rate depletion
- Operating income path to profitability
- Revenue growth (YoY and sequential)
- Gross margin and operating cash flow/FCF margin
Rockwell Medical, Inc.. (RMTI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.74x current ratio provides a solid financial cushion.
RMTI Profit Margin, ROE & Profitability Analysis
RMTI vs Healthcare Sector: How Rockwell Medical, Inc.. Compares
How Rockwell Medical, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Rockwell Medical, Inc.. Stock Overvalued? RMTI Valuation Analysis 2026
Based on fundamental analysis, Rockwell Medical, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Rockwell Medical, Inc.. Balance Sheet: RMTI Debt, Cash & Liquidity
RMTI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Rockwell Medical, Inc..'s revenue has grown significantly by 63% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.03 indicates the company is currently unprofitable.
RMTI Revenue Growth, EPS Growth & YoY Performance
RMTI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $17.3M | -$1.5M | $-0.04 |
| Q3 2025 | $15.9M | $276.0K | $0.01 |
| Q2 2025 | $16.1M | $343.0K | $0.01 |
| Q1 2025 | $18.9M | -$1.5M | $-0.04 |
| Q3 2024 | $23.8M | $276.0K | $0.01 |
| Q2 2024 | $18.1M | $343.0K | $0.01 |
| Q1 2024 | $19.7M | -$1.7M | $-0.06 |
| Q3 2023 | $18.7M | -$1.8M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Rockwell Medical, Inc.. Dividends, Buybacks & Capital Allocation
RMTI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Rockwell Medical, Inc.. (CIK: 0001041024)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RMTI
What is the AI rating for RMTI?
Rockwell Medical, Inc.. (RMTI) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 77% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RMTI's key strengths?
Claude: Strong liquidity position with current ratio of 3.74x and quick ratio of 3.43x. Conservative leverage with debt-to-equity ratio of only 0.23x limits financial risk. ChatGPT: Strong liquidity with 3.98x current and 3.63x quick ratios. Low leverage (0.24x debt/equity) providing flexibility.
What are the risks of investing in RMTI?
Claude: Catastrophic 31.8% revenue decline YoY indicates loss of market share or product demand collapse. Negative operating cash flow (-$167K) and free cash flow (-$592K) show company is not self-sustaining. ChatGPT: Continued double-digit revenue declines pressure scale and fixed-cost absorption. Persistent negative margins and returns (operating, net, ROE/ROA).
What is RMTI's revenue and growth?
Rockwell Medical, Inc.. reported revenue of $17.3M.
Does RMTI pay dividends?
Rockwell Medical, Inc.. does not currently pay dividends.
Where can I find RMTI SEC filings?
Official SEC filings for Rockwell Medical, Inc.. (CIK: 0001041024) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RMTI's EPS?
Rockwell Medical, Inc.. has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RMTI a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Rockwell Medical, Inc.. has a SELL rating with 77% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RMTI stock overvalued or undervalued?
Valuation metrics for RMTI: ROE of -4.5% (sector avg: 15%), net margin of -9.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RMTI stock in 2026?
Our dual AI analysis gives Rockwell Medical, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RMTI's free cash flow?
Rockwell Medical, Inc..'s operating cash flow is $-167.0K, with capital expenditures of $425.0K. FCF margin is -3.4%.
How does RMTI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9.3% (avg: 12%), ROE -4.5% (avg: 15%), current ratio 3.74 (avg: 2).